Rod Porter Consultancy works with charitable, academic and biotech organisations to help problem solving in their drug discovery research. Set-up in 2009, the company offers:

  • Medicinal chemistry consultancy from hit id to candidate selection
  • Particular expertise in the medicinal chemistry of CNS drug discovery
  • Screening hit analysis and follow-up
  • Input into lead optimisation, programme SAR analysis and strategy.
  • A focus on solving ADMET/PK problems
  • Independent, expert reviews of active programmes and projects
  • Review of therapeutic areas and new target opportunities
  • Review and unbiased critique of research proposals
  • Refereeing of research proposals
  • Third party due diligence
  • Support in protecting intellectual property

Clients include academic groups, the Wellcome Trust and SME’s covering the range from virtual to medium sized organisations and supporting venture capital funding activities. To discuss your needs and how Rod Porter Consultancy can help please make contact now.

My next confirmed meeting attednance will be at the Society of Medicines Research meeting Innovative partnerships for medicines research: how is the landscape evolving? 15th June at the Babraham Research Campus near Cambridge

The discovery and development of new drugs to treat many of society’s most complex and inadequately treated diseases remains a lengthy, high risk and high cost endeavour. While overall R&D costs continue to increase, the output in terms of new drug launches, especially for challenging diseases like cancer and neurodegenerative conditions, have failed to improve. Coupled to increasingly stringent requirements from regulators, payers and patients, endemically high attrition in Pharma R&D have prompted many in the research community to question the long-term viability of current drug discovery and development models.

The last decade has seen a dramatic increase in the number of new research institutes being established with the aim of improving the efficiency and success rates of drug discovery and development, by deploying innovative new business models. Central to the mission of these organizations is to identify improved routes for translation of novel preclinical research findings into more successful clinical outcomes; which still remains as one of the greatest challenges. New institutes from the academic, government, charitable and private funding sectors are increasingly being viewed as critical components of a new evolving eco-system focused on collaborative drug discovery and development.

This one day symposium follows on from a previous SMR meeting held in 2013 entitled, “Partnerships: Future Models for Drug Discovery”. It will explore how many of these institutes have developed and discuss how successful they have been in addressing some of the major challenges faced by the Pharma today. Bringing together senior representatives from Pharma, biotech, academia, public sector and charitable institutions, the impressive programme of speakers will highlight many innovative new models of drug discovery and development, together with some of the experiences, lessons learned and future strategies. At the close of the meeting, a panel discussion will be held with all the speakers, giving attendees an opportunity to engage in further debate around some of the topics presented.

My Newsletter is now in abeyance due to the closure of my mailing service and my need to focus on my clients requirements.  Please visit my blog which I will attempt to post to regularly with items that catch my eye also see my Twitter feed for the occasional tweet @Rodchem and @SocMedRes (Society of Medicines Research)

While I am able to offer a range of services in drug discovery from hit validation to candidate selection I have always been aware of areas where some teamwork would be good particularly in the hit id phase and for modelling support during hit validation and lead optimisation. I am therefore pleased to announce an informal association between Rod Porter Consultancy and CompChem Solutions. Rod Porter Consultancy will benefit from CompChem Solutions extensive molecular modelling expertise while conversely CompChem Solutions will be able to offer enhanced medicinal chemistry support for clients project.